Mercator Medical Group, a manufacturer of disposable gloves and distributor of medical materials, according to preliminary estimates, sustained its growth trajectory in the first quarter of 2025. The Group’s estimated consolidated revenues amounted to PLN 147.7 million, representing an increase of nearly 13% year-on-year. The consolidated EBITDA was estimated at PLN 5.4 million compared to a loss of PLN 4.2 million a year earlier, while net profit rose to PLN 30.6 million versus PLN 10.8 million in Q1 2024.
“In Q1 2025, maintaining calm, business balance, and consistency in executing previously adopted measures was crucial. The reported results confirm that our development goals based on operational stabilization and selective diversification are delivering tangible effects, even in the face of geopolitical challenges. The noticeable revenue growth results from effective commercial and operational activities. We consistently strengthen the Group’s foundations by maintaining adaptability and flexibility in a demanding market environment,” commented Monika Żyznowska, CEO of Mercator Medical S.A.
The first quarter of 2025 was characterized by increased uncertainty due to tensions in global trade policy and announcements of additional US tariffs on products originating from Asia, including Thailand — a key production region for the Group. In this uncertain environment, Mercator Medical analyzed the market and adapted all its actions to changing conditions while maintaining operational balance and the ability to meet sales targets.
“We achieved a significant year-on-year improvement in consolidated EBITDA. The net profit level was also positively impacted by a change in the approach to deferred tax calculation, following an individual tax interpretation regarding foreign exchange differences on loan repayments and currency conversions. It is also worth noting that the Group’s financial results still include costs related to development activities, which will start generating revenue only over time,” said Mariusz Popek, Member of the Management Board of Mercator Medical S.A.
In the real estate area, the Group continued its development activities through its subsidiary Mercator Estates. In January 2025, Maciej Wójcik assumed the position of CEO of the company. Currently, advanced conceptual works are underway for a prestigious revitalization project involving historic tenement houses located in the center of Kraków, which were acquired by the Group in autumn 2024.
Final financial results for Q1 2025 will be published according to the scheduled periodic reporting calendar.
